● Recruiting

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

Condition: Extrapulmonary Small Cell Carcinoma · Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

PhasePhase 2

Planned participants66

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a phase II, single-arm, multicenter study to evaluate the activity and safety of durvalumab in combination with carboplatin or cisplatin plus etoposide in patients with treated ES-EPSCC.

This description comes directly from the study's public registry record.

Talk to the study team

Carmine Pinto, MD · +39 0522296614 · carmine.pinto@ausl.re.it

Always discuss trial participation with your own doctor first.

Locations (1)

AUSL-IRCCS of Reggio Emilia

Reggio Emilia, Italy

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06464068